Open AccessBrief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)
Author(s) -
Albert Y. Liu,
Aliza Norwood,
Holly Gundacker,
Alex CarballoDiéguez,
Sherri Johnson,
Karen Patterson,
LindaGail Bekker,
Suwat Chariyalertsak,
Anupong Chitwarakorn,
Pedro Gonzáles,
Timothy H. Holtz,
Kenneth H. Mayer,
Carmen Zorrilla,
Susan Buchbinder,
Jeanna Piper,
Javier R. Lama,
Ross D. Cranston
Publication year - 2019
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002066
Subject(s) - microbicide , pre exposure prophylaxis , medicine , microbicides for sexually transmitted diseases , context (archaeology) , clinical trial , human immunodeficiency virus (hiv) , anal sex , men who have sex with men , family medicine , vaginal microbicide , gynecology , population , environmental health , health services , syphilis , paleontology , biology
As daily oral preexposure prophylaxis (PrEP) becomes standard for HIV prevention, routine use of PrEP is likely to increase within clinical trials of novel preventive agents. We describe the prevalence and characteristics of participants reporting nonstudy oral PrEP use within Microbicide Trials Network-017 (MTN-017), a phase 2 trial of a rectal microbicide.